Comparative Pharmacology
Head-to-head clinical analysis: SUFENTANIL CITRATE versus WESTADONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SUFENTANIL CITRATE versus WESTADONE.
SUFENTANIL CITRATE vs WESTADONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective mu-opioid receptor agonist; inhibits ascending pain pathways and alters pain perception and emotional response to pain.
Mu-opioid receptor agonist; also acts as an NMDA receptor antagonist and inhibits serotonin and norepinephrine reuptake.
0.5-5 mcg/kg IV/IM for induction of anesthesia; 0.1-0.3 mcg/kg IV for epidural analgesia; 0.3-0.8 mcg/kg IV for short operative procedures; maintenance with 0.1-0.3 mcg/kg IV every 1-2 hours as needed.
Oral: 2.5-10 mg every 4-6 hours as needed for pain; maximum 40 mg per day.
None Documented
None Documented
Terminal elimination half-life: 2-4 hours (adults), 1-3 hours (neonates), 3-6 hours (elderly). Context: context-sensitive half-time increases with infusion duration.
Terminal elimination half-life: 15-60 hours (mean ~24 hours). Clinical context: Prolonged half-life supports once-daily dosing in opioid maintenance; accumulation occurs with repeated dosing due to long half-life.
Renal (metabolites, <1% unchanged); fecal (biliary elimination of metabolites); approximately 80% renal, 20% fecal.
Primarily renal (40-50% as unchanged methadone and its metabolites, 15-20% as metadone-N-oxide), biliary/fecal (5-10%).
Category D/X
Category C
Opioid Agonist
Opioid Agonist